Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer’s disease
摘要:
High-throughput screening with cyclin-dependent kinase 5 (cdk5)/p25 led to the discovery of N-(5-isopropyl-thiazol-2-yl)isobutyramide (1). This compound is an equipotent inhibitor of cdk5 and cyclin-dependent kinase 2 (cdk2)/cyclin E (IC50 = ca. 320nM). Parallel and directed synthesis techniques were utilized to explore the SAR of this series. Up to 60-fold improvements in potency at cdk5 and 12-fold selectivity over cdk2 were achieved. (C) 2004 Elsevier Ltd. All rights reserved.
Unexpected rearrangement products from animations of 5-bromo-2-nitrothiazole
作者:Ho H. Lee、Brian D. Palmer、Maruta Boyd、William A. Denny
DOI:10.1002/jhet.5570330431
日期:1996.7
2-bromo-5-nitrothiazole (2) with weakly basic secondary aliphatic amines gives the expected 2-amino productsfrom nucleophilic displacement of the bromine, reaction of the isomeric 5-bromo-2-nitrothiazole (3) with such amines gives mixtures of the expected 5-amino products together with 2-aminated 5-nitrothiazole rearrangement products. The identity of the latter were detemined by alternative synthesis, and by X-ray
Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer’s disease
作者:Christopher J. Helal、Mark A. Sanner、Christopher B. Cooper、Thomas Gant、Mavis Adam、John C. Lucas、Zhijun Kang、Stanley Kupchinsky、Michael K. Ahlijanian、Bonnie Tate、Frank S. Menniti、Kristin Kelly、Marcia Peterson
DOI:10.1016/j.bmcl.2004.09.006
日期:2004.11
High-throughput screening with cyclin-dependent kinase 5 (cdk5)/p25 led to the discovery of N-(5-isopropyl-thiazol-2-yl)isobutyramide (1). This compound is an equipotent inhibitor of cdk5 and cyclin-dependent kinase 2 (cdk2)/cyclin E (IC50 = ca. 320nM). Parallel and directed synthesis techniques were utilized to explore the SAR of this series. Up to 60-fold improvements in potency at cdk5 and 12-fold selectivity over cdk2 were achieved. (C) 2004 Elsevier Ltd. All rights reserved.